Return to previous page
The results of the TRINITY study on the use in a single inhaler of the 3 types of inhalation medications used in COPD (Corticoid, Beta 2-agonist and muscarinic receptor antagonist) were published in the LANCET journal and revealed a 20% decrease in the number of Exacerbations. There is still no such inhaler of this type authorized for marketing, which is expected to happen next year and will change how patients with more severe COPD and which causes more symptoms are treated.The authors compared this drug with one of the most used currently and also with the 3 components, using 2 different inhalers.
Join Us on COPD360social
It is not our intention to serve as a substitute for medical advice and any content posted should not be used for medical advice, diagnosis or treatment. While we encourage individuals to share their personal experiences with COPD, please consult a physician before making changes to your own COPD management plan.